Background: Familial clustering of incident prostate cancer and some cancers at other discordant sites has been reported. Less is known about familial clustering of fatal prostate cancer with any fatal discordant cancers. Estimates on familial aggregation based on mortality are free from bias of overdiagnosis.
introduction
A family history of prostate cancer is a well-established risk factor for the disease [1, 2] . Familial clustering of prostate cancer with cancers at other discordant sites has also been reported, including breast, colon, and kidney cancers [3, 4] . The studies to date were mainly based on data on cancer incidence and only a few studies have taken the outcome (fatal or nonfatal disease) or clinical aggressiveness into account [5, 6] . We are not aware of a study on cancer mortality in individuals with a relative who died from prostate cancer. If a random proportion of prostate cancer patients died from prostate cancer, then the familial relative risk for death from prostate cancer should be equal or smaller than familial risks of diagnosis. This also holds for familial risk and mortality for discordant cancers. However, although the latest studies found no difference in the survival of familial and sporadic prostate cancer patients, there is evidence of familial clustering of good and poor survival [7] . These data suggest that familial subtypes of prostate cancer with a worse prognosis could exist or that progression of prostate cancer is caused by genetic or environmental factors shared within families. For example, an Icelandic study showed a worse survival of carriers of a BRCA2 founder mutation compared with noncarriers, and several studies report an increased risk for fatal prostate cancer in smokers while the risk for the disease itself is not increased or was even found to be decreased in smokers [8, 9] . If fatal forms of prostate cancer were associated with fatal forms of prostate or any other cancers, only data on familial mortality might be able to detect them. This would be a particularly relevant observation for clinical decision making and counseling. Furthermore, finding fatal subtypes of familial cancer would stimulate mechanistic and gene finding studies.
In the present study, we used the nationwide Swedish Family-Cancer Database to explore familial risks for incident and fatal prostate cancers with any discordant cancers in parent-offspring and sibling pairs. To exclude change findings due to multiple comparisons, we applied three independent tests for each pair of cancer sites: offspring prostate cancer by parental cancer X, offspring cancer X by parental prostate cancer, and sibling prostate cancer and cancer X. In addition to showing associations between incident prostate cancers and female cancers and urological cancer, we demonstrate for the first time that these clusters also include fatal cancers, some with higher familial risks than incident cancers.
patients and methods
The Swedish Family-Cancer Database was created in the 1990s by linking information from the Multigeneration Register, national censuses, Swedish Cancer Registry, and death notifications [10] . Data on family relationships were obtained from the Multigeneration Register, where children born in 1932 and later are registered with their biological parents as families. Thus, the individuals in the database can be divided into offspring generation (individuals born in 1932 and later) and parental generation. The Swedish Cancer Registry is based on compulsory reports of diagnosed cases, with coverage of the cancer registration close to 100% [11] . Cases are reported separately by clinicians and pathologists/cytologists; information on cancers based on death certificates is not used. The underlying cause of death was available from the Swedish Causes of Death Register. This register contains annually some 2000 notifications of cancer as an underlying cause of death that are not on file in the Cancer Registry; these cases were included in the analysis of familial mortality. The 2010 update of the database includes >12 million individuals and their cancers from years 1958 to 2008. Our study population constituted 7.8 million individuals from the offspring generation of the database with linkage to both parents. Most individuals without identified parents (1.8 million) were immigrants. The age structure of the database (offspring born after 1932) implicates that the maximum age of diagnosis in the offspring generation was 76 years. The age at diagnosis in the parental generation was not limited.
Standardized incidence ratios (SIRs) were calculated for diagnosis with prostate cancer when parents or siblings were diagnosed by cancer X. Additionally, we carried out analysis by reverse order, i.e. SIR for cancer X by paternal prostate cancer. This was a completely independent analysis. We also calculated SIR for prostate cancer by sibling cancer; however, this analysis was not independent. Standardized mortality ratios (SMRs) were used to compare cause-specific mortalities in individuals with a deceased parent or sibling with the cause-specific mortality rates in the general population. The number of individuals with both an affected or a deceased parent and sibling was too small for a separate analysis. Individuals entered the risk period at birth, immigration date, or 1 January 1961, whatever came last. Follow-up was terminated on emigration, absence at census, death, and 31 December 2008 (closing date of the study), whatever came first; when diagnosis of cancer was the event of interest, follow-up was also terminated at diagnosis of first malignancy. SIRs and SMRs were standardized for sex, age results Table 1 shows the SIRs for prostate cancer in offspring of parents diagnosed with cancer and SIRs for prostate cancer in siblings whose cosibling was diagnosed with cancer. Table 1 also shows SMR for death in prostate cancer when a relative had died of cancer. The number of familial incident cases far exceeded the number of familial deaths. The risk for incident prostate cancer was increased in offspring (SIR = 2.28) and siblings (SIR = 3.25) of prostate cancer patients. The risk for death from prostate cancer was similarly increased in offspring (SMR = 2.04) and siblings (SMR = 2.75) of individuals who died from prostate cancer. The SIR and the SMR were increased in offspring with a mother who was affected with ovarian cancer (SIR = 1.12) and who died from ovarian cancer (SMR = 1.66, 95% CI nonoverlapping with that of SIR). Sons and brothers of women affected with breast cancer were at increased risk for prostate cancer. In women who died from cervical cancer, the risk to die in prostate cancer was increased both for sons (SMR = 1.61) and brothers (SMR = 3.14, 95% CI nonoverlapping with that of SIR).
The SIRs and SMRs of any common cancer for individuals with a paternal or fraternal history of prostate cancer and death from prostate cancer are shown in Table 2 . For five discordant sites, we observed increased SIRs in offspring of fathers with prostate cancer (breast, endometrium, kidney, melanoma, leukemia). The SIRs for these sites ranged between 1.07 and 1.17. For individuals with a sibling history, we also observed increased SIRs for breast and kidney cancers and, additionally, for ovarian and urinary bladder cancers and non-Hodgkin's lymphoma. The SIRs were between 1.11 and 1.18. When fathers had died of prostate cancer, offspring were at an increased risk for fatal breast (SMR = 1.21) and kidney cancers (SMR = 1.23) and Hodgkin's disease (SMR = 1.67). The SIR and SMR in offspring were both decreased for lung cancer (SIR = 0.91, SMR = 0.91) and cancers of the upper aerodigestive tract (SIR = 0.90, SMR = 0.55). Furthermore, we observed decreased risks of esophageal cancer both in offspring and in siblings of prostate cancer patients.
discussion
Results on the familial aggregation of diagnosis with prostate cancer and discordant cancers have been published based on population databases from Utah and Iceland and previous versions of the Swedish Family-Cancer Database [3, 4, 12] . However, with a total of 36 000 prostate cancer patients and 262 000 discordant cancers, this is the largest study yet. Furthermore, this is the first study systematically reporting the familial clustering of mortality from prostate cancer and other cancers. The information on cancers and causes of death in our study were retrieved from nationwide registers. Studies on the validity of death certificates in Sweden have found that reporting of malignant neoplasm as the underlying cause of death is generally reliable [13, 14] . Thus, an important advantage was the accuracy and completeness of the analyzed data, which minimized biases related to over-and underreporting of family history, selection, and recall. This study, however, includes multiple comparisons. Internal validity of the study, i.e. increase in more than one of the three independent comparisons (risk for offspring prostate cancer by paternal cancer X, risk for offspring cancer X by parental prostate cancer, and sibling risks for prostate cancer and cancer X) and comparisons with previously published results from large population databases may suggest true association. However, when death from cancer was the outcome of interest, small number of familial deaths and lacking results on familial mortality from other population databases were limitations of these approaches. The number of familial deaths was small compared with the number of familial incident cases, especially for rare cancers and cancers with a good prognosis. Therefore, our study had the power to show statistically significant familial aggregation of death from prostate cancer and discordant cancers only for common cancers or effects that were larger than the effects seen for familial aggregation of incident cancers.
Following the introduction of opportunistic prostate-specific antigen-based screening for prostate cancer, large increases in the incidence have been observed worldwide [15, 16] . In Sweden, the average annual increase was 2.9% during 20 years up to 2005 when the trend turned to a decline [11] . As individuals with a close relative affected with cancer may take part in screening more often and earlier, the reported familial risks for prostate cancer based on diagnosed cases may be upward biased [17, 18] . This might also bias the estimates of the aggregation of prostate cancer and discordant cancers where screening is available such as breast cancer, melanoma, or cervical cancer. The estimates based on mortality provide a measure on familial risk free of overdiagnosis bias. The slightly lower familial risk for death from prostate cancer in comparison with the familial risk for diagnosis might point to an influence of overdiagnosis. Nevertheless, our data demonstrate that familial aggregation of prostate cancer is real and confirm previously observed risk patterns. Accordingly, the 
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increased risk for death from breast cancer in daughters of fathers who died from prostate cancer shows that the familial aggregation of prostate and breast cancers is not due to a higher prevalence of screening in relatives of cancer patients alone.
The observed familial risks for prostate cancer and discordant cancers in our study were smaller than 1.2. This finding is in line with the results of the studies from Utah and Iceland, where the highest risks were 1.3 [3, 4] . We found statistically significant association of diagnosis with prostate cancer and cancers at nine discordant sites for at least one comparison. Seven of these sites/cancer (breast, kidney, ovary, urinary bladder, melanoma, leukemia) were previously reported also from Iceland or Utah. We observed increased risks for endometrial cancer and Hodgkin's lymphoma in offspring of fathers with prostate cancer but these were solitary associations, confirmed neither in the two additional independent comparisons in our study nor in previous studies. Colon and thyroid gland cancers were more common in firstdegree relatives of prostate cancer patients both in Iceland and Utah but were not linked to prostate cancer in our study. Among the discordant sites where we observed association for diagnosis, the familial risk for death was increased for breast, kidney, and ovarian cancers. The magnitudes of the risk for death (SMRs) from breast and kidney cancers were only somewhat higher than the corresponding SIRs. Familial clustering of breast and prostate cancers has been reported in several studies [3, 4, 19] . The underlying mechanisms are unclear but biological similarities of breast and prostate tumors have been described [20] . An increased risk for kidney cancer in first-degree relatives of prostate cancer patients has been consistently demonstrated. In Sweden, families with hereditary prostate cancer showed an excess risk for kidney cancer [21] . A familial association of prostate and ovarian cancers was also demonstrated in Utah. In our study, the SMR of death from prostate cancer in sons of mothers who died from ovarian cancer exceeded the corresponding SIR with nonoverlapping 95% CIs. This observation might partly be explained by the occurrence of prostate cancer in BRCA2 mutation carriers: an Icelandic study reported a worse prognosis of prostate cancer for the carriers of the BRCA2 999del5 founder mutation [8] . If other mutations in BRCA2 were also associated with a worse survival, the risk for fatal prostate cancer might be particularly increased in offspring of ovarian cancer patients. However, mutations in BRCA2 account only for 1%-4% of ovarian cancers and the ovarian cancer survival of the mutation carriers appears to be better than that in sporadic ovarian cancer [8, 22] . Interestingly, fatal prostate cancer is associated with yet another female cancer: the SMRs for prostate cancer were 1.61 and 3.14 when mothers or sisters died of cervical cancer, respectively. It is unlikely that two high independent associations would occur by chance. Surprisingly, we found decreased risks for three smokingrelated cancers in the lung, esophagus, and upper aerodigestive tract in relatives of prostate cancer patients. A decreased risk for lung cancer in relatives of aggressive and nonaggressive prostate cancer patients has been reported before in a Finnish study [6] . The offered explanation was selection of prostate cancer patients to old age by healthier lifestyle. Smoking has been associated with a decreased risk for the common nonadvanced prostate cancer and an increased risk for advanced prostate cancer and poor survival [9] . Direct and indirect effects of smoking through hormonal and other mechanisms were thought to play a role. A number of interacting environmental and hormonal factors may potentially underlie the shared susceptibility and mortality between prostate and female breast, ovarian, and endometrial cancers, including obesity and physical inactivity [23] [24] [25] . However, considering that there is no significant spouse concordance between prostate cancer and female cancers, yet unidentified genetic factors may contribute to the findings [26] .
In summary, we confirmed the familial aggregation of prostate cancers and discordant cancers such as breast, kidney, and ovarian cancers. The increased risk for death from prostate and breast cancer in relatives of individuals who died from prostate cancer demonstrates that the familial clustering is not attributable to shared screening habits. The increased risk for death from prostate cancer in sons and brothers of women who died from ovarian and cervical cancers requires further research. These data might be useful for clinical counseling and they could guide the search for genes and shared environmental factors that are associated with these fatal cancers. 
